High-density lipoprotein cholesterol and residual cardiometabolic risk in metabolic syndrome
CP Cannon - Clinical cornerstone, 2007 - Elsevier
It has long been recognized that elevated levels of low-density lipoprotein cholesterol (LDL-
C) increase the risk of cardiovascular disease (CVD) and that pharmacologic therapy to
decrease LDL-C significantly reduces cardiovascular events. Despite the effectiveness of
statins for CVD risk reduction, even optimal LDL-lowering therapy alone fails to avert∼ 60%
to 70% of CVD cases, and the incidence of CVD mortality continues to grow. A low plasma
concentration of high-density lipoprotein cholesterol (HDL-C) is also associated with …
C) increase the risk of cardiovascular disease (CVD) and that pharmacologic therapy to
decrease LDL-C significantly reduces cardiovascular events. Despite the effectiveness of
statins for CVD risk reduction, even optimal LDL-lowering therapy alone fails to avert∼ 60%
to 70% of CVD cases, and the incidence of CVD mortality continues to grow. A low plasma
concentration of high-density lipoprotein cholesterol (HDL-C) is also associated with …